Skip to main content
Premium Trial:

Request an Annual Quote

Visby Medical Wins $12.3M BARDA Contract for Coronavirus, Flu Combo Test

NEW YORK — The US Department of Health and Human Services said on Tuesday that Visby Medical has been awarded a Biomedical Advanced Research and Development Authority contract worth $12.3 million to develop a handheld diagnostic for SARS-CoV-2 and influenza.

According to the HHS, the PCR-based test will be a version of Visby's single-use, fully integrated COVID-19 test, which provides results within 30 minutes and received Emergency Use Authorization in September, multiplexed to include the influenza A and B viruses.

While the SARS-CoV-2 test uses respiratory specimens collected by a healthcare provider or self-collected in a healthcare setting, the new test will be designed for both point-of-care and at-home use as an over-the-counter product, the HHS said.

San Jose, California-based Visby, which was awarded $19 million from the National Institutes of Health last year to develop a single-use gonorrhea test, said that the BARDA contract could be extended to run for a total of 38 months with up to $48.7 million in funding. The company is expected to first seek FDA EUA for the multiplex test, followed by a submission for 510(k) clearance.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.